HRP20211908T1 - Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa - Google Patents

Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa Download PDF

Info

Publication number
HRP20211908T1
HRP20211908T1 HRP20211908TT HRP20211908T HRP20211908T1 HR P20211908 T1 HRP20211908 T1 HR P20211908T1 HR P20211908T T HRP20211908T T HR P20211908TT HR P20211908 T HRP20211908 T HR P20211908T HR P20211908 T1 HRP20211908 T1 HR P20211908T1
Authority
HR
Croatia
Prior art keywords
group
cnp variant
seq
nos
use according
Prior art date
Application number
HRP20211908TT
Other languages
English (en)
Croatian (hr)
Inventor
Charles A. O'neill
Todd M. Oppeneer
Jason K. Pinkstaff
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of HRP20211908T1 publication Critical patent/HRP20211908T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20211908TT 2015-12-08 2016-12-08 Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa HRP20211908T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis
EP16852866.9A EP3386531B1 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Publications (1)

Publication Number Publication Date
HRP20211908T1 true HRP20211908T1 (hr) 2022-03-04

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211908TT HRP20211908T1 (hr) 2015-12-08 2016-12-08 Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa

Country Status (17)

Country Link
US (2) US11202819B2 (enExample)
EP (2) EP4019038A3 (enExample)
JP (1) JP7104625B2 (enExample)
KR (1) KR102941538B1 (enExample)
CN (1) CN108697766A (enExample)
AU (2) AU2016365751B2 (enExample)
CA (1) CA3007315A1 (enExample)
DK (1) DK3386531T3 (enExample)
ES (1) ES2901769T3 (enExample)
HR (1) HRP20211908T1 (enExample)
HU (1) HUE057083T2 (enExample)
IL (1) IL259690B2 (enExample)
MX (1) MX2018006986A (enExample)
PL (1) PL3386531T3 (enExample)
PT (1) PT3386531T (enExample)
RU (1) RU2759679C2 (enExample)
WO (1) WO2017100400A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー/エス 環部分にキャリア結合を有するcnpプロドラッグ
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
EP4710947A3 (en) 2016-01-08 2026-06-17 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
KR102518217B1 (ko) 2016-01-08 2023-04-04 아센디스 파마 그로우쓰 디스오더스 에이/에스 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
CN112752556A (zh) * 2018-04-27 2021-05-04 雷米生物科学公司 新的医疗装置、递送运载体及其制造
EP3923906A1 (en) * 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
CN116635027A (zh) * 2020-11-25 2023-08-22 普罗林科斯有限责任公司 C-利钠肽的延长释放水凝胶偶联物
WO2022240936A1 (en) * 2021-05-11 2022-11-17 Texas Tech University System Targeted selenium conjugates as countermeasures for pathogenic viruses and cells
CA3242257A1 (en) * 2021-12-07 2023-06-15 Biomarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
KR102866559B1 (ko) 2022-11-02 2025-10-02 노보 노르디스크 에이/에스 Cnp 화합물
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
KR20250098109A (ko) * 2023-12-21 2025-07-01 주식회사 펩트론 나트륨이뇨 펩타이드 유사체 및 이의 용도
CN117801123B (zh) * 2024-02-29 2024-05-03 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Cnp類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
KR20070007842A (ko) * 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
ES2465141T3 (es) * 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
EP2432489B1 (en) 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
JP6055779B2 (ja) * 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ, インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法

Also Published As

Publication number Publication date
AU2016365751A1 (en) 2018-06-21
RU2021132347A (ru) 2022-03-24
EP4019038A2 (en) 2022-06-29
CA3007315A1 (en) 2017-06-15
PL3386531T3 (pl) 2022-02-28
AU2016365751B2 (en) 2023-12-21
RU2759679C2 (ru) 2021-11-16
PT3386531T (pt) 2021-12-29
KR20180088459A (ko) 2018-08-03
US11202819B2 (en) 2021-12-21
IL259690B (en) 2022-10-01
US12214015B2 (en) 2025-02-04
EP3386531B1 (en) 2021-10-13
RU2018124600A3 (enExample) 2020-01-13
ES2901769T3 (es) 2022-03-23
RU2018124600A (ru) 2020-01-13
AU2024201852A1 (en) 2024-04-11
WO2017100400A3 (en) 2017-10-26
EP3386531A2 (en) 2018-10-17
US20190247467A1 (en) 2019-08-15
EP4019038A3 (en) 2022-09-28
JP7104625B2 (ja) 2022-07-21
CN108697766A (zh) 2018-10-23
MX2018006986A (es) 2018-09-05
WO2017100400A2 (en) 2017-06-15
JP2019505486A (ja) 2019-02-28
KR102941538B1 (ko) 2026-03-19
IL259690A (en) 2018-07-31
DK3386531T3 (da) 2022-01-03
HUE057083T2 (hu) 2022-04-28
US20220160836A1 (en) 2022-05-26
IL259690B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
RU2018124600A (ru) Применение вариантов натрийуретического пептида типа с для лечения остеоартрита
JP2019505486A5 (enExample)
Oddis et al. A subluxing arthropathy associated with the anti‐Jo‐1 antibody in polymyositis/dermatomyositis
HRP20200268T1 (hr) Pripravci antisklerotinskih antitijela u visokim koncentracijama
HRP20210277T1 (hr) Pripravak za kontroliranu stimulaciju jajnika
PH12019501900A1 (en) Treatment of hidradenitis suppurativa
CN103622013A (zh) 一种供关节炎患者食用含骨胶原肽的食品配方
HRP20140888T1 (hr) Humana monoklonalna protutijela za humani il-4
HRP20241491T1 (hr) Pripravci i metode za liječenje homocistinurije
Bettany-Saltikov et al. Ergonomically designed kneeling chairs are they worth it?: Comparison of sagittal lumbar curvature in two different seating postures
ES2579828T3 (es) Composición para la prevención y el tratamiento de la artritis reumatoide
Luo et al. Finite element analysis of the biomechanical effects of manipulation of lower limb hyperextension on the sacroiliac joint
Habibi et al. Idiopathic chondrolysis in a child: think beyond JIA.
Oleas-Santillán et al. Anterior Hip Dislocation from post-injection gluteal muscular fibrosis: case report
Panotopoulos et al. Orthopedic interventions in patients with hemophilia
Kumar Dry gangrene of fingers and injection site pain following accidental intra-arterial injection: case report
Barati et al. Identifying base position for women’s thoracolumbar fascia ultrasound
CN204812197U (zh) 一种老年人防摔骨折保护裤
Joseph et al. Fractures in boys with Duchenne muscular dystrophy and their relationship to age
Lee et al. SAT0497 effect of raloxifene on osteoporosis and disease activity in postmenopausal female with rheumatic diseases
Rodríguez et al. Unilateral generalized morphea: a case and literature review
Subrata Chakrabarti et al. Rheumatoid arthritis in a case of primary biliary cirrhosis-an unusual association.
MX2022004676A (es) Composicion farmaceutica de extractos de plantas para tratar fibromialgia, artritis reumatoide, lupus y otras enfermedades autoinmunes.
CN104490503A (zh) 一种髋部护具
Lei MIIT and NHFPC Jointly Promote Smart Home Healthy Old-age Nursing